Ovid Therapeutics (OVID) EPS (Weighted Average and Diluted) (2020 - 2025)
Historic EPS (Weighted Average and Diluted) for Ovid Therapeutics (OVID) over the last 6 years, with Q3 2025 value amounting to -$168.01.
- Ovid Therapeutics' EPS (Weighted Average and Diluted) rose 1336.12% to -$168.01 in Q3 2025 from the same period last year, while for Sep 2025 it was -$502.43, marking a year-over-year increase of 4803.86%. This contributed to the annual value of -$0.37 for FY2024, which is 9994.88% up from last year.
- As of Q3 2025, Ovid Therapeutics' EPS (Weighted Average and Diluted) stood at -$168.01, which was up 1336.12% from -$64.73 recorded in Q2 2025.
- Over the past 5 years, Ovid Therapeutics' EPS (Weighted Average and Diluted) peaked at $117.61 during Q2 2024, and registered a low of -$728.12 during Q4 2023.
- Moreover, its 5-year median value for EPS (Weighted Average and Diluted) was -$0.21 (2022), whereas its average is -$70.57.
- As far as peak fluctuations go, Ovid Therapeutics' EPS (Weighted Average and Diluted) plummeted by 45497500.0% in 2023, and later soared by 6543888.89% in 2024.
- Over the past 5 years, Ovid Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.38 in 2021, then skyrocketed by 57.89% to -$0.16 in 2022, then plummeted by 454975.0% to -$728.12 in 2023, then skyrocketed by 99.98% to -$0.13 in 2024, then crashed by 128645.49% to -$168.01 in 2025.
- Its last three reported values are -$168.01 in Q3 2025, -$64.73 for Q2 2025, and -$141.57 during Q1 2025.